CIK Cell Transfusion Plus Gefitinib As Second Or Third-Line Treatment for Advanced Adenocarcinoma Non-Small Cell Lung Cancer

• Age between 18 to 80 years
• Histologically or cytologically proven advanced adenocarcinoma non-small-cell lung cancer
• Life expectancy more than 12 weeks
• Not received EGFR agent or cell immunotherapy before entry into this study
• World Health Organization- Eastern Cooperative Oncology Group Performance Status 0-3
• Gefitinib as the second or third line therapy
• More than 4 weeks must have completion of the last dose of chemotherapy, radiation therapy, investigational therapy and patients must adequately recover from these effects
• Disease measurable
• Patients must have adequate organ and marrow functions as defined below: white blood cells: more than 3.0×109/L, Neutrophils: more than 1.5×109/L, Platelets: more than 75×109/L, Hemoglobin more than 80g/L, Serum total bilirubin less than 1.25 folds of the upper normal limit (ULN), Serum glutamic-oxal (o) acetic transaminase: less than 2.5×ULN, Serum glutamate pyruvate transaminase: less than 2.5×ULN, Serum creatinine: less than 1.25×ULN, Blood urea nitrogen: less than 2×ULN.
• Pregnancy test: the test of women of child-bearing period must be negative before entry into this study
• Subject must have good compliance and voluntarily to sign a written informed consent

Exclusion Criteria:

• Acute infection
• Uncontrolled concurrent illness: hypersensitiveness, asthma, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, serious heart valve disease
• Psychiatric illness, pharmacological dependence, or other situation that would limit compliance with study requirements
• History of other neoplasms
• Coagulation disorder and bleeding tendency
• Pertinacious hypertension（systolic blood pressure > 140 mmHg or diastolic blood pressure > 90 mmHg) after aggressive therapy
• Brain metastasis with symptomatic
• Severe liver dysfunction
• Autoimmune disease (e.g. systemic lupus erythematosus, rheumatoid arthritis, thyroadenitis, et al )
• Patients who diagnosed as virus hepatitis, syphilis or HIV, or other infectious diseases
• Employment of corticosteroids or other immunodepressive hormone therapies
• With main organs transplantation
• Pregnant or lactating women
• Known or suspected in patients with severe hypersensitivity to CIK or gefitinib or to any other component of gefitinib
• Patients receiving any other investigational agents in 30 days or prepare to participate in other investigation in the clinical period